Senior HealthcareGeriatric Pharmacology & Medication Safety

Polypharmacy in Older Adults: Drug Interactions, the Beers Criteria, and Deprescribing

Polypharmacy—the concurrent use of 5 or more prescription medications—affects over 40% of older adults, significantly increasing the risk of adverse drug reactions, cognitive decline, falls, and prescribing cascades. Review the AGS Beers Criteria for potentially inappropriate medications, anticholinergic burden, and structured deprescribing protocols.

Published: 2026-09-13Reviewed: September 2026Updated: 2026-09-15 9 min read 1590 Views
Listen to this guide Audio Edition

Hands-free audio narration

Educational Health Notice

This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.

Polypharmacy in Older Adults: Drug Interactions, the Beers Criteria, and Deprescribing

Quick Summary & Key Findings

Polypharmacy is defined as taking 5 or more daily medications and is a major risk factor for adverse drug events, delirium, orthostatic hypotension, and falls in older adults due to age-related declines in hepatic clearance and renal elimination. The American Geriatrics Society (AGS) Beers Criteria identifies high-risk drugs that should generally be avoided or deprescribed in seniors, including first-generation antihistamines (diphenhydramine), benzodiazepines, long-term PPIs, and non-selective NSAIDs.

In geriatric medicine, medications that were safe and clinically appropriate in midlife often become hazardous as the body ages. Natural pharmacokinetic and pharmacodynamic shifts—including decreased glomerular filtration rate (eGFR), diminished hepatic cytochrome P450 enzyme activity, decreased total body water, and increased relative adipose tissue—alter drug clearance and prolong biological half-lives.

Polypharmacy is defined as the regular use of five or more medications, while 'hyperpolypharmacy' describes regimens containing ten or more daily drugs. In many cases, polypharmacy arises through a 'prescribing cascade': an adverse drug side effect is misdiagnosed as a new medical condition, prompting the addition of another prescription drug to treat the symptom caused by the first.

Conducting regular, structured medication reviews and utilizing the evidence-based AGS Beers Criteria allows clinicians, patients, and caregivers to safely deprescribe inappropriate medications, reduce adverse interactions, and improve quality of life.

The AGS Beers Criteria: High-Risk Medications in Seniors

The American Geriatrics Society (AGS) Beers Criteria categorizes medications whose risks typically outweigh their clinical benefits in patients aged 65 and older:
First-Generation Antihistamines (Diphenhydramine, Hydroxyzine): Highly anticholinergic; causes severe dry mouth, urinary retention in men, constipation, blurred vision, acute confusion, and doubles fall risk.
Benzodiazepines & Z-Drug Sedatives (Lorazepam, Zolpidem, Alprazolam): Associated with daytime sedation, cognitive impairment, motor vehicle accidents, and hip fractures.
Chronic NSAIDs (Ibuprofen, Naproxen, Meloxicam): Triggers severe gastrointestinal ulceration/bleeding, acute kidney injury (worsening CKD), and elevated blood pressure.
Long-Term Proton Pump Inhibitors (PPIs - Omeprazole, Pantoprazole): When used beyond 8 weeks without clear indication, linked to hypomagnesemia, vitamin B12 deficiency, bone fractures, and *Clostridioides difficile* infections.
Antipsychotics in Dementia: Carries a black-box warning for increased stroke and all-cause mortality when used for dementia-related behavioral symptoms.

Cumulative Anticholinergic Burden and Cognitive Decline

Many commonly prescribed drugs possess subtle anticholinergic properties (e.g., overactive bladder drugs like oxybutynin, tricyclic antidepressants, muscle relaxants):
Anticholinergic Cognitive Burden (ACB) Scale: Scores drugs from 1 (mild) to 3 (severe). A cumulative score ≥3 is associated with a 50% higher risk of cognitive decline and dementia over time.
Cholinergic Blockade: Acetylcholine is the primary neurotransmitter responsible for attention, memory encoding, and parasympathetic visceral tone; blocking it induces acute delirium in vulnerable brains.

The 5-Step Clinical Deprescribing Protocol

Deprescribing is the systematic, supervised process of dose reduction or medication withdrawal to discontinue drugs whose harms exceed their benefits:
1. Complete Medication Reconciliation: Compile a 'brown bag' review containing every prescription, OTC supplement, herbal remedy, and eye drop.
2. Identify Inappropriate or Redundant Drugs: Cross-reference against Beers Criteria and STOPP/START guidelines.
3. Prioritize Deprescribing Targets: Focus first on drugs without current clinical indication, highest adverse risk, or treating an unneeded prescribing cascade.
4. Structured Tapering: Gradually reduce dosages under medical supervision to avoid withdrawal symptoms or rebound effects (e.g., tapering PPIs to prevent rebound acid hypersecretion).
5. Regular Monitoring: Evaluate symptom stability and functional improvements at 4 and 8 weeks.

Frequently Asked Questions

P
Clinical Reviewer License Verified

Dr. Prasun Chatterjee, MBBS, MD (Geriatrics)

Professor & Head, Department of Geriatric Medicine, AIIMS New Delhi • MBBS, MD (Geriatric Medicine)
Medical Review Board

Dr. Prasun Chatterjee is Professor in the Department of Geriatric Medicine at the All India Institute of Medical Sciences (AIIMS), New Delhi. A leading authority on healthy longevity, memory clinics, dementia care, and geriatric polypharmacy, he oversees clinical guidance on senior health and longevity.

License ID: DMC-13924
Professor, Department of Geriatric Medicine, AIIMS, Ansari Nagar, New Delhi
Medically evaluated on September 2026View Dr. Profile, Verified Credentials & Articles

References & Clinical Resources

  1. Clinical Research Faculty & Editorial Team. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2020-2026). [Access Resource Link] — Journal of the American Geriatrics Society (JAGS)
  2. Clinical Research Faculty & Editorial Team. Deprescribing in Older Adults with Multimorbidity and Polypharmacy (2020-2026). [Access Resource Link] — JAMA / Journal of the American Medical Association
  3. Clinical Research Faculty & Editorial Team. STOPP/START Criteria for Potentially Inappropriate Prescribing in Older People: Version 3 (2020-2026). [Access Resource Link] — European Geriatric Medicine
Article Tools & Sharing:
Educational Resources
Patient Community Doctor Reviewed

Reader Reviews & Clinical Q&A

Real experiences, reader questions, and verified physician guidance.

5.0 out of 5 (2 reviews)
GB
Gerald B., Age 72Verified Reader
•August 18, 2026

At 72, I was concerned about muscle loss and fatigue. Implementing the protein distribution and resistance training suggestions here has significantly improved my balance and energy levels.

Dr. Prasun Chatterjee, MBBS, MD (Geriatrics)Geriatrician & Clinical Reviewer
August 19, 2026

That is wonderful to hear, Gerald! Preserving lean muscle mass and motor unit recruitment through progressive resistance training is the foundation of healthy longevity.

DS
Dr. Steven P., GeriatricianHealthcare Professional
•August 29, 2026

The inclusion of the AGS Beers Criteria and anticholinergic risk scores makes this an invaluable educational asset for patients and families navigating polypharmacy.

Dr. Prasun Chatterjee, MBBS, MD (Geriatrics)Geriatrician & Clinical Reviewer
August 30, 2026

Deprescribing and medication reconciliation are critical safety imperatives in geriatric care, Dr. Steven. Thank you for championing patient safety.

Leave a Review or Ask a Medical Question

5 / 5 Stars
* Reviews are reviewed by our clinical editorial team in accordance with our medical policies.